These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 3533642)

  • 1. Design of dihydrofolate reductase inhibitors from X-ray crystal structures.
    Roth B
    Fed Proc; 1986 Nov; 45(12):2765-72. PubMed ID: 3533642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 2.13 A structure of E. coli dihydrofolate reductase bound to a novel competitive inhibitor reveals a new binding surface involving the M20 loop region.
    Summerfield RL; Daigle DM; Mayer S; Mallik D; Hughes DW; Jackson SG; Sulek M; Organ MG; Brown ED; Junop MS
    J Med Chem; 2006 Nov; 49(24):6977-86. PubMed ID: 17125251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Basis of selectivity of antibacterial diaminopyrimidines.
    Baccanari DP; Kuyper LF
    J Chemother; 1993 Dec; 5(6):393-9. PubMed ID: 8195830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased hydrophobic interactions of iclaprim with Staphylococcus aureus dihydrofolate reductase are responsible for the increase in affinity and antibacterial activity.
    Oefner C; Bandera M; Haldimann A; Laue H; Schulz H; Mukhija S; Parisi S; Weiss L; Lociuro S; Dale GE
    J Antimicrob Chemother; 2009 Apr; 63(4):687-98. PubMed ID: 19211577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2,4-Diamino-5-benzylpyrimidines as antibacterial agents. 7. Analysis of the effect of 3,5-dialkyl substituent size and shape on binding to four different dihydrofolate reductase enzymes.
    Roth B; Rauckman BS; Ferone R; Baccanari DP; Champness JN; Hyde RM
    J Med Chem; 1987 Feb; 30(2):348-56. PubMed ID: 3100802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of ionic interactions in ligand binding and catalysis of R67 dihydrofolate reductase.
    Hicks SN; Smiley RD; Hamilton JB; Howell EE
    Biochemistry; 2003 Sep; 42(36):10569-78. PubMed ID: 12962480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based approach to pharmacophore identification, in silico screening, and three-dimensional quantitative structure-activity relationship studies for inhibitors of Trypanosoma cruzi dihydrofolate reductase function.
    Schormann N; Senkovich O; Walker K; Wright DL; Anderson AC; Rosowsky A; Ananthan S; Shinkre B; Velu S; Chattopadhyay D
    Proteins; 2008 Dec; 73(4):889-901. PubMed ID: 18536013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New insights into DHFR interactions: analysis of Pneumocystis carinii and mouse DHFR complexes with NADPH and two highly potent 5-(omega-carboxy(alkyloxy) trimethoprim derivatives reveals conformational correlations with activity and novel parallel ring stacking interactions.
    Cody V; Pace J; Chisum K; Rosowsky A
    Proteins; 2006 Dec; 65(4):959-69. PubMed ID: 17019704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structures of dihydrofolate reductase-thymidylate synthase of Trypanosoma cruzi in the folate-free state and in complex with two antifolate drugs, trimetrexate and methotrexate.
    Senkovich O; Schormann N; Chattopadhyay D
    Acta Crystallogr D Biol Crystallogr; 2009 Jul; 65(Pt 7):704-16. PubMed ID: 19564691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel dihydrofolate reductase inhibitors. Structure-based versus diversity-based library design and high-throughput synthesis and screening.
    Wyss PC; Gerber P; Hartman PG; Hubschwerlen C; Locher H; Marty HP; Stahl M
    J Med Chem; 2003 Jun; 46(12):2304-12. PubMed ID: 12773035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein flexibility and species specificity in structure-based drug discovery: dihydrofolate reductase as a test system.
    Bowman AL; Lerner MG; Carlson HA
    J Am Chem Soc; 2007 Mar; 129(12):3634-40. PubMed ID: 17335207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Solution of the conformation and alignment tensors for the binding of trimethoprim and its analogs to dihydrofolate reductase: 3D-quantitative structure-activity relationship study using molecular shape analysis, 3-way partial least-squares regression, and 3-way factor analysis.
    Dunn WJ; Hopfinger AJ; Catana C; Duraiswami C
    J Med Chem; 1996 Nov; 39(24):4825-32. PubMed ID: 8941396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Receptor-based design of dihydrofolate reductase inhibitors: comparison of crystallographically determined enzyme binding with enzyme affinity in a series of carboxy-substituted trimethoprim analogues.
    Kuyper LF; Roth B; Baccanari DP; Ferone R; Beddell CR; Champness JN; Stammers DK; Dann JG; Norrington FE; Baker DJ
    J Med Chem; 1985 Mar; 28(3):303-11. PubMed ID: 3973902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three-dimensional structure of M. tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs.
    Li R; Sirawaraporn R; Chitnumsub P; Sirawaraporn W; Wooden J; Athappilly F; Turley S; Hol WG
    J Mol Biol; 2000 Jan; 295(2):307-23. PubMed ID: 10623528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-based design of lipophilic quinazoline inhibitors of thymidylate synthase.
    Jones TR; Varney MD; Webber SE; Lewis KK; Marzoni GP; Palmer CL; Kathardekar V; Welsh KM; Webber S; Matthews DA; Appelt K; Smith WW; Janson CA; Villafranca JE; Bacquet RJ; Howland EF; Booth CL; Herrmann SM; Ward RW; White J; Moomaw EW; Bartlett CA; Morse CA
    J Med Chem; 1996 Feb; 39(4):904-17. PubMed ID: 8632414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The crystal structure of dihydrofolate reductase from Thermotoga maritima: molecular features of thermostability.
    Dams T; Auerbach G; Bader G; Jacob U; Ploom T; Huber R; Jaenicke R
    J Mol Biol; 2000 Mar; 297(3):659-72. PubMed ID: 10731419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thermodynamic study of dihydrofolate reductase inhibitor selectivity.
    Sasso SP; Gilli RM; Sari JC; Rimet OS; Briand CM
    Biochim Biophys Acta; 1994 Jul; 1207(1):74-9. PubMed ID: 8043612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-based design and synthesis of lipophilic 2,4-diamino-6-substituted quinazolines and their evaluation as inhibitors of dihydrofolate reductases and potential antitumor agents.
    Gangjee A; Vidwans AP; Vasudevan A; Queener SF; Kisliuk RL; Cody V; Li R; Galitsky N; Luft JR; Pangborn W
    J Med Chem; 1998 Aug; 41(18):3426-34. PubMed ID: 9719595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
    Kuyper LF; Baccanari DP; Jones ML; Hunter RN; Tansik RL; Joyner SS; Boytos CM; Rudolph SK; Knick V; Wilson HR; Caddell JM; Friedman HS; Comley JC; Stables JN
    J Med Chem; 1996 Feb; 39(4):892-903. PubMed ID: 8632413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specificity in structure-based drug design: identification of a novel, selective inhibitor of Pneumocystis carinii dihydrofolate reductase.
    Gschwend DA; Sirawaraporn W; Santi DV; Kuntz ID
    Proteins; 1997 Sep; 29(1):59-67. PubMed ID: 9294866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.